MX2009009388A - Formulaciones liquidas de sales de 4-[2-(4-metilfenilsulfanil)feni l]-piperidina. - Google Patents

Formulaciones liquidas de sales de 4-[2-(4-metilfenilsulfanil)feni l]-piperidina.

Info

Publication number
MX2009009388A
MX2009009388A MX2009009388A MX2009009388A MX2009009388A MX 2009009388 A MX2009009388 A MX 2009009388A MX 2009009388 A MX2009009388 A MX 2009009388A MX 2009009388 A MX2009009388 A MX 2009009388A MX 2009009388 A MX2009009388 A MX 2009009388A
Authority
MX
Mexico
Prior art keywords
methylphenylsulfanyl
piperidine
salts
liquid formulations
phen
Prior art date
Application number
MX2009009388A
Other languages
English (en)
Inventor
Heidi Lopez De Diego
Gudrun Lasskogen
Tine Bryan Stensboel
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2009009388A publication Critical patent/MX2009009388A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporcionan formulaciones líquidas de sales específicas de 4-[2-(4-metilfenilsulfanil)fenil]piperidina.
MX2009009388A 2007-03-20 2008-03-14 Formulaciones liquidas de sales de 4-[2-(4-metilfenilsulfanil)feni l]-piperidina. MX2009009388A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
DKPA200701790 2007-12-14
PCT/DK2008/050062 WO2008113358A1 (en) 2007-03-20 2008-03-14 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine

Publications (1)

Publication Number Publication Date
MX2009009388A true MX2009009388A (es) 2009-11-25

Family

ID=39327217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009388A MX2009009388A (es) 2007-03-20 2008-03-14 Formulaciones liquidas de sales de 4-[2-(4-metilfenilsulfanil)feni l]-piperidina.

Country Status (27)

Country Link
US (1) US20100105730A1 (es)
EP (2) EP2388004A1 (es)
JP (1) JP5301474B2 (es)
KR (1) KR20090130000A (es)
AR (1) AR065796A1 (es)
AT (1) ATE526966T1 (es)
AU (1) AU2008228637B2 (es)
BR (1) BRPI0808820A2 (es)
CA (1) CA2684592C (es)
CL (1) CL2008000797A1 (es)
CO (1) CO6220958A2 (es)
CY (1) CY1112285T1 (es)
DK (1) DK2129377T3 (es)
EA (1) EA019695B1 (es)
ES (1) ES2373275T3 (es)
HK (1) HK1140949A1 (es)
HR (1) HRP20110844T1 (es)
IL (1) IL200959A (es)
MX (1) MX2009009388A (es)
MY (1) MY148695A (es)
NZ (1) NZ579717A (es)
PL (1) PL2129377T3 (es)
PT (1) PT2129377E (es)
RS (1) RS52050B (es)
SI (1) SI2129377T1 (es)
TW (1) TWI405588B (es)
WO (1) WO2008113358A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151632A1 (en) * 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
EA021122B1 (ru) * 2009-04-24 2015-04-30 Х. Лундбекк А/С Жидкие составы солей 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
SG185081A1 (en) 2010-04-30 2012-12-28 Takeda Pharmaceutical Enteric tablet
KR20130060220A (ko) 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163326A1 (de) * 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
JP4405802B2 (ja) * 2001-10-16 2010-01-27 メディカル・インスティル・テクノロジーズ・インコーポレイテッド 計量された量の物質を供給するための、密閉チャンバ及び一方向弁を備えたディスペンサ
DE10202367A1 (de) 2002-01-23 2003-09-25 Duerr Dental Gmbh Co Kg Applikator für flüssige oder viskose Substanzen
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
KR101367136B1 (ko) * 2007-07-27 2014-02-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 이의 제조 방법

Also Published As

Publication number Publication date
EA200970869A1 (ru) 2010-02-26
CL2008000797A1 (es) 2008-09-26
AU2008228637A1 (en) 2008-09-25
SI2129377T1 (sl) 2012-01-31
EP2129377B1 (en) 2011-10-05
BRPI0808820A2 (pt) 2014-08-19
IL200959A (en) 2011-12-29
NZ579717A (en) 2012-06-29
JP5301474B2 (ja) 2013-09-25
US20100105730A1 (en) 2010-04-29
AR065796A1 (es) 2009-07-01
CO6220958A2 (es) 2010-11-19
CY1112285T1 (el) 2015-12-09
JP2010521500A (ja) 2010-06-24
IL200959A0 (en) 2010-05-17
EP2388004A1 (en) 2011-11-23
PT2129377E (pt) 2011-12-23
CA2684592A1 (en) 2008-09-25
DK2129377T3 (da) 2012-01-02
EA019695B1 (ru) 2014-05-30
CA2684592C (en) 2013-11-12
WO2008113358A1 (en) 2008-09-25
TWI405588B (zh) 2013-08-21
ES2373275T3 (es) 2012-02-01
ATE526966T1 (de) 2011-10-15
HRP20110844T1 (hr) 2011-12-31
AU2008228637B2 (en) 2013-03-21
EP2129377A1 (en) 2009-12-09
TW200902083A (en) 2009-01-16
KR20090130000A (ko) 2009-12-17
PL2129377T3 (pl) 2012-02-29
MY148695A (en) 2013-05-31
RS52050B (en) 2012-04-30
HK1140949A1 (en) 2010-10-29

Similar Documents

Publication Publication Date Title
UA97660C2 (ru) Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина
IN2012DN03337A (es)
IL237820A (en) Using a History of 4- (1-Carboxy-Ethylcarbamoyl) -4- (5- [2,1] Ditheolan-3-Il-Pentanoylamino) - Butyric Acid for Drug Preparation
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MY138941A (en) Aryl-pyridine derivatives
MX2010005824A (es) Derivados de aminotiazol.
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
EA201001334A1 (ru) Твёрдый препарат гидрохлорида карипразина для перорального введения
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
NZ600310A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
EA201290116A1 (ru) Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
MX2011012344A (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoi co y acido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino) butilo.
GEP20125704B (en) Plk kinase inhibitors
TN2011000504A1 (en) Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl) phenyl] piperazine
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
UA108711C2 (uk) Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
NZ605827A (en) Co-crystals and salts of ccr3-inhibitors
MX2009013501A (es) Compuestos piperidinicos y sus usos.
MX2009009388A (es) Formulaciones liquidas de sales de 4-[2-(4-metilfenilsulfanil)feni l]-piperidina.
MX2010005714A (es) Compuestos de piridina.

Legal Events

Date Code Title Description
FG Grant or registration